PRECLINICAL RADIOIMMUNOTHERAPY WITH AN INTERNALIZING MAB
PRECLINICAL RADIOIMMUNOTHERAPY WITH AN INTERNALIZING MAB
批准号:
2100646
负责人:
RHONA N STEIN
金额:
$19.74万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-07-20 至 1997-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The ability of antibodies to target tumors in vivo and provide reduction
in tumor burden has been well documented, but many of the issues
pertaining to the selection of an optimal radionuclide-MAb conjugate
remain unresolved. The aim of this project is to examine important
variables of radioimmunotherapy (RAIT) for the treatment of cancer which
relate to the ability of a MAb to internalize into antigen bearing cells.
RS7-3G11 is the primary antibody to be used in this project, and has been
selected due to a number of promising characteristics. Our preliminary
results indicate that RS7-3G11 demonstrates: a) a high frequency of
antigen expression on a wide variety of tumor types, especially lung,
bladder, breast, cervical, ovarian, prostate, and stomach cancers, with
limited expression on normal human tissue; b) the ability to localize to
tumor in an animal model; c) the ability to provide reduction in tumor
burden in vivo when conjugated to 131I; and d) the ability to rapidly
internalize into antigen-bearing cells. The ability to internalize into
target cells was not seen with many other MAbs possessing the other
positive characteristics, and is a promising property of RS7-3G11 which
will enable us to utilize RS7-3G11 in comparative studies on the
importance of antibody internalization in RAIT. The proposal is divided
into areas of evaluation which are designed to study the selection of
radionuclide-MAb conjugate providing the best tumoricidal activity
covering (a) choice of radionuclide and labeling technology in
relationship to whether or not an antibody internalizes, and (b)
evaluations of the biological effects of RAIT with these conjugates and
the cellular processing of the radionuclide-MAb conjugates. These studies
are designed taking into account the descriptions of the uptake and
distribution of antibodies to solid tumors which have been generated using
mathematical modeling, and we will assess whether the results we obtain
experimentally conform to the predictions of the models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Doxorubicin-Immunoconjugate Therapy of Non-Hodgkin's Lymphoma
-
批准号:7192572
-
项目类别:
-
资助金额:$25.52万
-
财政年份:2006
-
负责人:RHONA N STEIN
-
依托单位:
Doxorubicin-Immunoconjugate Therapy of Non-Hodgkin's Lymphoma
-
批准号:7029430
-
项目类别:
-
资助金额:$28.06万
-
财政年份:2006
-
负责人:RHONA N STEIN
-
依托单位:
Doxorubicin-Immunoconjugate Therapy of Non-Hodgkin's Lymphoma
-
批准号:7365272
-
项目类别:
-
资助金额:$25.52万
-
财政年份:2006
-
负责人:RHONA N STEIN
-
依托单位:
PRE-CLINICAL COMBINATION CHEMO- AND RADIOANTIBODY THERAP
-
批准号:6868172
-
项目类别:
-
资助金额:$100.65万
-
财政年份:2002
-
负责人:RHONA N STEIN
-
依托单位:
FACSCALIBUR FLOW CYTOMETER SYSTEM
-
批准号:6053834
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2000
-
负责人:RHONA N STEIN
-
依托单位:
RAIT OF LUNG CANCER WITH RESIDUALIZING LABELS
-
批准号:2467953
-
项目类别:
-
资助金额:$33.0万
-
财政年份:1994
-
负责人:RHONA N STEIN
-
依托单位:
PRECLINICAL RADIOIMMUNOTHERAPY WITH AN INTERNALIZING MAB
-
批准号:2100647
-
项目类别:
-
资助金额:$19.14万
-
财政年份:1994
-
负责人:RHONA N STEIN
-
依托单位:
RAIT OF LUNG CANCER WITH RESIDUALIZING LABELS
-
批准号:6150144
-
项目类别:
-
资助金额:$35.87万
-
财政年份:1994
-
负责人:RHONA N STEIN
-
依托单位:
RAIT OF LUNG CANCER WITH RESIDUALIZING LABELS
-
批准号:2871799
-
项目类别:
-
资助金额:$34.87万
-
财政年份:1994
-
负责人:RHONA N STEIN
-
依托单位:
PRECLINICAL RADIOIMMUNOTHERAPY WITH AN INTERNALIZING MAB
-
批准号:2100645
-
项目类别:
-
资助金额:$18.23万
-
财政年份:1994
-
负责人:RHONA N STEIN
-
依托单位:
海外基金